CLDX News and Press, Celldex Therapeutics Inc. From 11/19/25

2025-11-19 15:01:02 ET The last time I spoke about Enanta Pharmaceuticals, Inc. ( ENTA ) it was in a Seeking Alpha article entitled "Enanta: Despite Primary Endpoint Miss Zelicapavir Could Benefit From Trial Design Change." I noted then that this company had failed to me...

2025-11-10 16:12:51 ET More on Celldex Celldex Therapeutics: Caution Warranted After Big Rebound (Rating Downgrade) Celldex Therapeutics, Inc. (CLDX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript Celldex: Despite Dropping Eosinophilic...

Strong execution and continued progress across pipeline Positive Phase 2 barzolvolimab data in Chronic Spontaneous Urticaria (CSU) demonstrating rapid, profound improvement in UCT7 scores with sustained disease control post treatment and strong efficacy regardless of baseline IgE levels ...

HAMPTON, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ: CLDX) today announced the appointment of Teri Lawver as Senior Vice President, Chief Commercial Officer. Ms. Lawver is an accomplished global healthcare executive with 30 years of strategic, commercial launch and operating P&L ...

HAMPTON, N.J., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today that management will participate in fireside chats at the following upcoming investor conferences: Guggenheim 2 nd Annual Healthcare Innovation Conference on Tuesday, November 11 at 10:00 am ET TD...

HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab’s ability to improve urticaria control from the Company’s recently completed Phase 2 study in chronic spontaneous u...

First large, randomized, placebo-controlled study to demonstrate clinical benefit in patients with Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) All primary and secondary endpoints met with high statistical significance at 12 weeks and sustained through end of treatment period...

Curaleaf Holdings Inc (CURLF) is expected to report $-0.07 for Q3 2025 Southwest Gas Holdings Inc. (DE) (SWX) is expected to report $0.09 for Q3 2025 Terreno Realty Corporation (TRNO) is expected to report $0.65 for Q3 2025 Bio-Techne Corp (TECH) is expected to report $0.36 for Q1 202...

--Data from Phase 1 Study in healthy volunteers presented at CIA Biennial Symposium-- HAMPTON, N.J., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today positive data from the ongoing Phase 1 study of CDX-622, a novel bispecific antibody that targets two non-redundan...

2025-10-13 14:35:33 ET Shares of mast cell therapy concern Celldex Therapeutics, Inc. ( CLDX ) have rallied just over 70% off their 60-month April 2025 low that was caused by high discontinuation rates for lead asset barzolvolimab. The company’s only significant candidate has...